Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my ...

Company advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with lead candidate, SENTI-202, in clinical development for ...

Investment analysts at StockNews.com initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Free Report) in a report issued on Monday. The firm set a “sell” rating on the biotechnology ...

"It's way more important than anything I do on the field. I love what I do on the field, but, I mean, this is what it's really about," Howard said.